key: cord-0316272-gq3s2d3c
authors: Singh, R.; Krishnasamy, S.; Meena, J. K.; Sirohiya, P.; Kumar, B.; Ratre, B. K.; Vig, S.; Pandit, A.; Sagiraju, H. K. R.; Gupta, R.; Bhatnagar, S.
title: Outcomes of COVID-19 infection in patients with chronic kidney disease on maintenance hemodialysis at a COVID hospital in India
date: 2022-01-07
journal: nan
DOI: 10.1101/2022.01.07.22268915
sha: a6d593dede4ef9ebb56dda608f4268ac29eca8bd
doc_id: 316272
cord_uid: gq3s2d3c

Background: Patients with chronic kidney disease (CKD) on hemodialysis are highly vulnerable to COVID-19 infection with a mortality rate higher than the rest of the population. There are several clinical and laboratory parameters that can predict the course and the outcomes in this group of population. Methods: We retrospectively collected the baseline demographic, clinical, in-hospital, and laboratory data of the patients with CKD on maintenance hemodialysis who were admitted to our COVID-19 hospital during the first and the second wave. Results: We obtained data for 35 patients from the first and 5 patients from the second wave. The analysis of the data for 35 patients from the first wave revealed shortness of breath (62.9%), and fever (54.3%) being the most common presenting symptoms, and the majority of the patients (57.2 %) presented with moderate to severe disease at admission with 57 % had bilateral lung infiltrates, and required oxygen support (65.7%) at admission. The comparison of clinical and laboratory markers between survivors (27 patients, 77.1%) and non-survivors (8 patients, 22.9%) revealed an older age, severe disease at presentation, invasive mechanical ventilation, baseline severe lymphocytopenia, high serum glutamic oxaloacetic transaminase, blood urea, and inflammatory markers like Interleukin-6 and procalcitonin, fibrinogen and low albumin in non survivors. Conclusions: The older age, severe disease at presentation, the requirement of invasive mechanical ventilation, raised baseline Interleukin-6, procalcitonin, serum glutamic oxaloacetic transaminase, blood urea and a low albumin level could be valuable predictors of poor outcomes.

The course of Coronavirus disease 2019 (COVID-19) infection in patients with pre-existing kidney disease is quite severe and associated with high mortality as observed across the recent literature. A high vulnerability to infections had been observed in patients with chronic kidney disease (CKD) on maintenance hemodialysis(1) with an increased risk of severe disease and poor outcomes upon infection with COVID-19. ( 2) The dysregulation of immune response and coagulation abnormalities are postulated to be involved in the immunopathological process. (3) The older age, the burden of comorbidities, and frailty of CKD patients on maintenance dialysis together with inflammatory stress imposed by the infection pose high vulnerability to the worse outcomes. (4, 5) The clinical characteristics and in-hospital course of CKD patients with COVID-19 infection and outcomes in terms of in-hospital mortality were studied retrospectively from the medical records. The comparison of clinical and laboratory parameters between survivors and non-survivors revealed a variety of factors that can affect and predict the clinical course of COVID-19 infection in these patients. We highlighted these factors in the Indian patients with CKD on maintenance hemodialysis who were admitted to the COVID-19 hospital at National Cancer Institute (NCI), All India Institute of Medical Sciences (AIIMS), Jhajjar during both the waves of COVID-19 from July 2020 to June 2021. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 7, 2022. ; https://doi.org/10.1101/2022.01.07.22268915 doi: medRxiv preprint

This was a retrospective record review conducted at a tertiary care institute, National Cancer Institute (NCI), All India Institute of Medical Sciences (AIIMS) at Jhajjar, India. During the pandemic, the institute had been designated as a COVID hospital. The study protocol was approved by the Institute Ethics Committee of AIIMS, New Delhi. The protocol was designed and drafted following the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) checklist. From the hospital electronic database, we included all consecutive patients who were known cases of CKD on maintenance hemodialysis with the existence of COVID-19 infection confirmed by the real-time polymerase chain reaction (RT-PCR) test from the nasopharyngeal swab sample. We excluded patients with inadequate data from the study.

We retrospectively collected the clinical data from the case files, screening forms, and treatment sheets. The laboratory parameters were abstracted into excel datasheet from the hospital electronic patient information portal. The demographic parameters like age, gender, comorbidities status, vital parameters including oxygen saturation at presentation, hemodialysis sessions, complication during or after the dialysis, medical treatment administered, course of disease during hospitalization, lab parameters at baseline, length of hospital stay and the outcomes in terms of discharge or death at end of hospitalization were collected.

Mild COVID-19: Patients with baseline oxygen saturation ≥ 94% on room air without breathlessness but with other symptoms suggestive of COVID-19 such as fever, sore throat, myalgia, fatigue etc. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. and Fisher's exact tests for quantitative and qualitative data respectively. A P-value less than 0.05 was considered significant.

In the first wave of COVID-19, a total of 43 patients underwent dialysis at our facility, 36 patients among them were CKD on maintenance hemodialysis, and 7 were acute kidney injury (AKI) patients. One patient was excluded from the study because of inadequate data. Among these 35 patients, 8 patients (22.9%) died during the hospital stay and 27 patients (77.1%) were discharged. In the second wave, a total of 20 patients underwent hemodialysis of which only 5 patients were CKD on maintenance dialysis while the rest 15 were AKI patients. Three of (60%) All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 7, 2022. ; https://doi.org/10.1101/2022.01.07.22268915 doi: medRxiv preprint them were discharged and two (40%) didn't survive. All the patients from both the waves who had in-hospital mortality died from the complications of COVID-19 infection.

The baseline clinico-demographic characteristics of the patients from the first wave are shown in Table 1 . The median (IQR) age of the patients were 51 (42.5-63.5) years, ranging from 28 and 84 years with 25.7% patients were over 65 years of age. The median (IQR) age in the second wave were 62 (53-75) years, ranging from 50 to 77 years Hypertension was the most common among co-morbidities with a prevalence of 91.4%, followed by diabetes in 34.3%. The median (IQR) days between symptom onset to hospitalization was 5 (2-7.5) days. The most common presenting symptoms were shortness of breath (SOB) (62.9%), fever (54.3%), and cough (45.7%) in descending order. The severity of infection was mild in most cases (42.9%), moderate (28.6%), and severe (28.6%) in the rest. Twenty-three patients (65.7%) required oxygen supplementation at admission to the hospital. A similar clinico-demographic profile was observed in 5 patients of the second wave of COVID-19.

The baseline findings in hematologic parameters were a decreased mean absolute lymphocyte counts (ALC), high neutrophil-lymphocyte ratio (NLR) and a mild decrease in platelet counts. A baseline high blood urea, and serum creatinine values were observed. The markers of inflammation, C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin (PCT), ferritin, fibrinogen and D-dimer were also high at admission. The coagulation profile showed nearnormal PT, APPT, and INR. A similar trend was observed in patients from the second wave with a slightly higher baseline TLC, NLR, blood urea, and serum creatinine levels. The baseline chest X-ray (CXR) was suggestive of bilateral infiltrates in 57% and 80% of the patients in the first All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 7, 2022. ; https://doi.org/10.1101/2022.01.07.22268915 doi: medRxiv preprint and second wave respectively. The median (IQR) values of baseline laboratory findings in survivors and non-survivor patients in the first wave are shown in Table 3 .

After an initial admission, the severity of disease progressed in few patients subsequently requiring transfer from ward, or high dependency unit ( Table 2 .

The comparison of clinico-demographic features, in-hospital management and outcomes between survivors and non-survivors has been included in Table 1 , Table 2 respectively. There was a significant difference between median (IQR) age between non-survivors versus survivors 70 (54-74) years and 49 (42-55) years respectively. The severity of COVID-19 infection at admission was also high in the non-survivor group. Seventy-five per cent (75%) of patients had the severe 1 0 COVID-19 disease at admission in the non-survivor group with the presence of bilateral infiltrates on chest X-ray and requirement of oxygen and respiratory support in all patients at admission. In the survivor group, 52% of the patients had mild disease at admission with no requirement of oxygen or respiratory support in 44% of patients at admission. All the patients in the non-survivors group received higher antibiotics, antivirals, antifungals, steroids, off label and emergency use authorization (EUA) drugs following the escalation of the medical treatment. All 6 patients who required IMV during the first wave and 2 patients in the second wave didn't survive. There were no differences in median (IQR) days of the length of hospital stay between two groups 13 (11-17) versus 14.5 (4.2-18.7) days.

The comparison of baseline laboratory parameters between survivors and non-survivors has been shown in Table 3 and (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 7, 2022. ; https://doi.org/10.1101/2022.01.07.22268915 doi: medRxiv preprint fibrinogen, blood urea, serum aspartate aminotransferase (SGOT), and a significantly low absolute lymphocyte count and albumin level were found in patients who had experienced unfavourable outcomes. These findings suggested that a low albumin level, coagulation abnormalities, severe inflammation, and deteriorating renal function increased the risk of mortality in these patients. A similar trend of raised inflammatory markers and high blood urea levels was observed in patients with unfavourable outcomes in the second wave, although the data were not analysed further for analysis and comparison due to the very small size of the sample (5 patients only). We observed mortality of 23% in our patients which correspond to the similar range of mortality of 16-32% reported in a similar group of patients across the various recent studies. (2) (3) (4) (5) The complication of severe COVID-19 disease leading to acute respiratory distress syndrome (ARDS) with or without multiorgan dysfunction (MOD) was the cause of mortality in all the patients, a similar observation was reported in other previous studies as well. (6) (7) (8) The patients with CKD on maintenance dialysis have impaired immune function. (9) The elevation in levels of inflammatory markers suggest that they exert an immunological response to the coronavirus infection and the cytokines have a key role to play in its immunopathology.

(10)A high CRP level is associated with worse outcomes(2-6,11) and a similar finding in our patients supports the evidence though there was no significant elevation in non-survivors. The elevation in IL-6 and PCT were also associated with in-hospital death in infected patients. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 7, 2022. ; https://doi.org/10.1101/2022.01.07.22268915 doi: medRxiv preprint Regarding coagulation abnormalities, in our study elevated fibrinogen, D-dimer was observed in a majority of the patients, with a significant elevation of fibrinogen in non-survivors. The presence of coagulation abnormalities has been well established by previous studies in patients with COVID-19. (3,8,17 ) Thus, coagulation abnormalities had a higher incident rate in CKD patients on maintenance dialysis and a significant derangement is associated with poor outcomes.

Other laboratory parameters like increased TLC, Neutrophil Lymphocyte Ratio (NLR), and lymphocytopenia are also associated with poor outcomes(3-6), we also observed similar findings in our study where TLC, NLR was significantly elevated in the mortality group. In routine investigations, a baseline high blood urea, SGOT, and potassium levels were associated with higher mortality in this group of patients (2, 5) , and similar findings were noted by us also. A low albumin level was also associated with poor outcome in these patients (2) (3) (4) (5) , that was also one of the significant findings in our study.

There are several limitations in our study, the first one being the small sample size, so the findings of the study cannot be extrapolated to the whole population of CKD patients on maintenance dialysis. Although our observations are in coherence with the findings of similar studies conducted elsewhere in the world, and a few prognostic factors are universal in this group of patients. The second limitation being the inherent information and selection bias during retrospective data retrieval. The third limitation is a very small number of CKD patients who underwent dialysis in the second wave of the COVID-19. We couldn't compare the clinical characteristics and outcomes between the first and second wave and couldn't come to any conclusion in this aspect. In the current literature, there are mostly retrospective studies on this group of patients so, there is a need for future similar prospective studies with an adequate All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 7, 2022. ; https://doi.org/10.1101/2022.01.07.22268915 doi: medRxiv preprint 1 4 sample size for better interpretation of the prognostic parameters and their association with clinical outcomes.

The observation from our study led to the conclusion that the CKD patients on maintenance hemodialysis are the group of patients that are more susceptible to severe disease following infection with coronavirus due to the presence of multiple co-morbidities, frailty, and older age.

The older age, severe disease at presentation, the requirement of oxygen and respiratory support, baseline elevated inflammatory markers especially IL-6, PCT, raised fibrinogen level and a low albumin level are associated with mortality or poor outcomes in these patients.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 7, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 7, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 7, 2022. ; https://doi.org/10.1101/2022.01.07.22268915 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 7, 2022. ; https://doi.org/10.1101/2022.01.07.22268915 doi: medRxiv preprint

Mortality caused by sepsis in patients with end-stage renal disease compared with the general population

Clinical characteristics of deceased hemodialysis patients affected by COVID-19

Clinical course of patients on maintenance hemodialysis and COVID-19: a retrospective longitudinal study

Identifying prognostic risk factors for poor outcome following COVID-19 disease among in-centre haemodialysis patients: role of inflammation and frailty

Determinants of mortality in a large group of hemodialysis patients hospitalized for COVID-19

COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain

Clinical characteristics and outcome of hemodialysis patients with COVID-19: a large cohort study in a single Chinese center

Immunologic function and survival in hemodialysis patients

Into the eye of the cytokine storm

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

IL-6 may be a good biomarker for earlier detection of COVID-19 progression

IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 7, 2022. ; https://doi.org/10.1101/2022.01.07.22268915 doi: medRxiv preprint